Camurus AB (publ) (0RD1.L)
0RD1.L Stock Price Chart
Explore Camurus AB (publ) interactive price chart. Choose custom timeframes to analyze 0RD1.L price movements and trends.
0RD1.L Company Profile
Discover essential business fundamentals and corporate details for Camurus AB (publ) (0RD1.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
3 May 2016
Employees
238.00
Website
https://www.camurus.comCEO
Fredrik Tiberg
Description
Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
0RD1.L Financial Timeline
Browse a chronological timeline of Camurus AB (publ) corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 11 Feb 2026
Upcoming earnings on 6 Nov 2025
Earnings released on 17 Jul 2025
EPS came in at kr 4.08 surpassing the estimated kr 3.42 by +19.30%, while revenue for the quarter reached kr 675.20M, beating expectations by +6.02%.
Earnings released on 15 May 2025
EPS came in at kr 3.35 surpassing the estimated kr 2.92 by +14.73%, while revenue for the quarter reached kr 558.34M, missing expectations by -15.47%.
Earnings released on 13 Feb 2025
EPS came in at kr 2.45 surpassing the estimated kr 1.86 by +31.72%, while revenue for the quarter reached kr 553.13M, beating expectations by +3.30%.
Earnings released on 7 Nov 2024
EPS came in at kr 2.16 surpassing the estimated kr 1.56 by +38.46%, while revenue for the quarter reached kr 479.60M, missing expectations by -3.76%.
Earnings released on 16 Jul 2024
EPS came in at kr 1.25 falling short of the estimated kr 1.47 by -14.97%, while revenue for the quarter reached kr 444.87M, missing expectations by -0.69%.
Earnings released on 8 May 2024
EPS came in at kr 1.32 surpassing the estimated kr 1.09 by +21.10%, while revenue for the quarter reached kr 389.99M, missing expectations by -5.23%.
Earnings released on 5 Mar 2024
EPS came in at -kr 0.27 surpassing the estimated -kr 1.75 by +84.39%, while revenue for the quarter reached kr 374.57M, missing expectations by -0.14%.
Earnings released on 30 Sept 2023
EPS came in at kr 1.50 surpassing the estimated kr 0.71 by +112.16%, while revenue for the quarter reached kr 383.99M, beating expectations by +17.48%.
Earnings released on 30 Jun 2023
EPS came in at kr 5.24 surpassing the estimated kr 4.31 by +21.58%, while revenue for the quarter reached kr 674.26M, beating expectations by +13.94%.
Earnings released on 31 Mar 2023
EPS came in at kr 1.02 surpassing the estimated kr 0.46 by +123.19%, while revenue for the quarter reached kr 284.04M, missing expectations by -2.21%.
Earnings released on 31 Dec 2022
EPS came in at kr 0.23 falling short of the estimated kr 0.29 by -22.91%, while revenue for the quarter reached kr 268.02M, missing expectations by -0.48%.
Earnings released on 30 Sept 2022
EPS came in at kr 0.61 surpassing the estimated kr 0.07 by +724.95%, while revenue for the quarter reached kr 241.36M, missing expectations by -1.23%.
Earnings released on 30 Jun 2022
EPS came in at kr 0.14 surpassing the estimated -kr 0.20 by +172.03%, while revenue for the quarter reached kr 226.68M, beating expectations by +2.09%.
Earnings released on 31 Mar 2022
EPS came in at -kr 0.01 surpassing the estimated -kr 0.22 by +93.74%, while revenue for the quarter reached kr 220.28M, beating expectations by +9.05%.
Dividend declared on 15 Mar 2022
A dividend of kr 0.29 per share was announced, adjusted to kr 0.29.
Earnings released on 31 Dec 2021
EPS came in at -kr 0.26 surpassing the estimated -kr 0.32 by +20.91%, while revenue for the quarter reached kr 182.79M, beating expectations by +3.07%.
Earnings released on 30 Sept 2021
EPS came in at -kr 0.11 surpassing the estimated -kr 0.32 by +65.14%, while revenue for the quarter reached kr 153.98M, missing expectations by -13.18%.
Earnings released on 30 Jun 2021
EPS came in at -kr 0.89, while revenue for the quarter reached kr 137.90M.
Earnings released on 31 Mar 2021
EPS came in at -kr 0.40, while revenue for the quarter reached kr 125.90M.
Earnings released on 31 Dec 2020
EPS came in at -kr 1.22, while revenue for the quarter reached kr 105.57M.
Earnings released on 30 Sept 2020
EPS came in at -kr 0.38, while revenue for the quarter reached kr 100.26M.
0RD1.L Stock Performance
Access detailed 0RD1.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.